Helen Torley sold $1.1M of HALO
PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 16,569 shares at an average of $68.92, traded Dec 1, 2025, filed Dec 1, 2025.
Score components
- +25RoleCEO
- +25Trade size$1.1M at market
- 0Share of holdings soldSold 2.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001159036-25-000063, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2025 | GGift Common Stock10b5-1 | -25,000 | $0.00 | $0 | 708,719 | Dec 1, 2025 |
| Dec 1, 2025 | MOption exercise Common Stock10b5-1 | +16,569 | $8.11 | $134k | 725,288 | Dec 1, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -10,406 | $68.51 | $713k | 714,882 | Dec 1, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -5,402 | $69.44 | $375k | 709,480 | Dec 1, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -500 | $70.36 | $35k | 708,980 | Dec 1, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -261 | $71.60 | $19k | 708,719 | Dec 1, 2025 |
| Dec 1, 2025 | MOption exercise Option to Purchase Common Stockderivative10b5-1 | -16,569 | $8.11 | $134k | 0 | Dec 1, 2025 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 58Moderate | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $2.0M 28,857 shares | -84% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.5M 50,000 shares | -6% | |
| 15Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $3.9M 50,000 shares | -7% | |
| 6Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $141k 2,000 shares | -5% | |
| 44Moderate | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $278k 4,263 shares | -25% | |
| 10Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $59k 829 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.